



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Award

Award# 5 NU62PS924625-03-00

FAIN# NU62PS924625

Federal Award Date: 07/14/2022

Recipient Information

1. Recipient Name

Health and Senior Services, Missouri Department of
920 WILDWOOD DR
Missouri Department of Health and Senior Services
JEFFERSON CITY, MO 65109-5796
[NO DATA]

2. Congressional District of Recipient

03

3. Payment System Identifier (ID)

[REDACTED]

4. Employer Identification Number (EIN)

[REDACTED]

5. Data Universal Numbering System (DUNS)

878092600

6. Recipient's Unique Entity Identifier (UEI)

UETLXV8NG8F4

7. Project Director or Principal Investigator

Alicia Jenkins
ALICIA.JENKINS@HEALTH.MO.GOV
5737516431

8. Authorized Official

Ms. Marcia A Mahaney
Director
Marcia.Mahaney@health.mo.gov
573-751-6014

Federal Agency Information

CDC Office of Financial Resources

9. Awarding Agency Contact Information

Rhonda Burton
Grants Management Specialist
bgr2@cdc.gov
770-488-1381

10. Program Official Contact Information

Orazie Slayton
wye7@cdc.gov
770-488-5553

Federal Award Information

11. Award Number

5 NU62PS924625-03-00

12. Unique Federal Award Identification Number (FAIN)

NU62PS924625

13. Statutory Authority

This Program is authorized under section 318 of the Public Health Service Act (42 U.S.C. Section 247c, as amended)

14. Federal Award Project Title

PS20-2010: Integrated HIV Programs for Health Departments to Support Ending the HIV Epidemic in the United States

15. Assistance Listing Number

93.940

16. Assistance Listing Program Title

HIV Prevention Activities\_Health Department Based

17. Award Action Type

Non-Competing Continuation

18. Is the Award R&D?

No

Summary Federal Award Financial Information

Table with 2 columns: Item Number and Amount. Includes rows for Budget Period Start Date, Total Amount of Federal Funds Obligated, Authorized Carryover, and Total Federal and Non-Federal Approved this Budget Period.

28. Authorized Treatment of Program Income

ADDITIONAL COSTS

29. Grants Management Officer - Signature

Ms. Portia Brewer
Grants Management Officer

30. Remarks

Non-Competing Continuation: Financial Assistance in the amount of \$3,041,420.00



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Award

Award# 5 NU62PS924625-03-00  
 FAIN# NU62PS924625  
 Federal Award Date: 07/14/2022

<b>Recipient Information</b>	
<b>Recipient Name</b> Health and Senior Services, Missouri Department of 920 WILDWOOD DR Missouri Department of Health and Senior Services JEFFERSON CITY, MO 65109-5796 [NO DATA]	
<b>Congressional District of Recipient</b> 03	
<b>Payment Account Number and Type</b> [REDACTED]	
<b>Employer Identification Number (EIN) Data</b> [REDACTED]	
<b>Universal Numbering System (DUNS)</b> 878092600	
<b>Recipient's Unique Entity Identifier (UEI)</b> UETLXV8NG8F4	
<b>31. Assistance Type</b> Cooperative Agreement	
<b>32. Type of Award</b> Other	

<b>33. Approved Budget</b> (Excludes Direct Assistance)	
I. Financial Assistance from the Federal Awarding Agency Only	
II. Total project costs including grant funds and all other financial participation	
a. Salaries and Wages	\$92,594.00
b. Fringe Benefits	\$58,899.00
c. Total Personnel Costs	\$151,493.00
d. Equipment	\$0.00
e. Supplies	\$404,690.00
f. Travel	\$14,737.00
g. Construction	\$0.00
h. Other	\$4,859.00
i. Contractual	\$2,436,857.00
j. TOTAL DIRECT COSTS	\$3,012,636.00
k. INDIRECT COSTS	\$28,784.00
l. TOTAL APPROVED BUDGET	\$3,041,420.00
m. Federal Share	\$3,041,420.00
n. Non-Federal Share	\$0.00

**34. Accounting Classification Codes**

FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	OBJECT CLASS	CFDA NO.	AMT ACTION FINANCIAL ASSISTANCE	APPROPRIATION
0-9390C1K	20NU62PS924625	PS	41.51	93.940	\$0.00	75-20-0950
0-9390EU4	20NU62PS924625	PS	41.51	93.940	\$0.00	75-20-0950
0-9390EU5	20NU62PS924625	PS	41.51	93.940	\$0.00	75-20-0950
1-9390EU4	20NU62PS924625	PS	41.51	93.940	\$0.00	75-21-0950
1-9390EU5	20NU62PS924625	PS	41.51	93.940	\$0.00	75-21-0950
1-9390H40	20NU62PS924625	PS	41.51	93.940	\$0.00	75-21-0950
2-9390EU4	20NU62PS924625	PS	41.51	93.940	\$2,519,930.00	75-22-0950
2-9390EU5	20NU62PS924625	PS	41.51	93.940	\$521,490.00	75-22-0950



**DEPARTMENT OF HEALTH AND HUMAN SERVICES** Notice of Award

Centers for Disease Control and Prevention

Award# 5 NU62PS924625-03-00

FAIN# NU62PS924625

Federal Award Date: 07/14/2022

**Direct Assistance**

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
<b>Total</b>	<b>\$0.00</b>	<b>\$0.00</b>	<b>\$0.00</b>

## AWARD ATTACHMENTS

Health and Senior Services, Missouri Department of

5 NU62PS924625-03-00

---

1. Terms and Conditions

## AWARD INFORMATION

**Incorporation:** In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at <https://www.cdc.gov/grants/federal-regulations-policies/index.html>, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number **CDC-RFA-PS20-2010**, entitled “**Integrated HIV Programs for Health Departments to Support Ending the HIV Epidemic in the United States**”, and application dated **April 14, 2022**, as may be amended, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NoA).

**Approved Funding:** Funding in the amount of **\$3,041,420** is approved for the Year **03** budget period, which is **August 1, 2022** through **July 31, 2023**. All future year funding will be based on satisfactory programmatic progress and the availability of funds.

**Component Funding:**

**Component A**            **\$2,519,930**

**Component B**            **\$521,490**

**Total Funding**        **\$3,041,420**

The federal award amount is subject to adjustment based on total allowable costs incurred and/or the value of any third party in-kind contribution when applicable.

Note: Refer to the Payment Information section for Payment Management System (PMS) subaccount information.

**This award has been fully funded for budget year 03.**

**Financial Assistance Mechanism:** Cooperative Agreement

**Substantial Involvement by CDC:** This is a cooperative agreement and CDC will have substantial programmatic involvement after the award is made. Substantial involvement is in addition to all post-award monitoring, technical assistance, and performance reviews undertaken in the normal course of stewardship of federal funds.

CDC program staff will assist, coordinate, or participate in carrying out effort under the award, and recipients agree to the responsibilities therein, as detailed in the NOFO.

1. Collaborate to ensure coordination and implementation of strategies to support the implementation of comprehensive HIV surveillance and prevention activities.
2. Provide guidance and coordination to funded organizations to improve the quality and effectiveness of work plans, evaluation strategies, products and services, and collaborative activities with other organizations.
3. Collaborate to ensure coordination and provide policy and program information for rapid dissemination and implementation.
4. Work with recipients to identify and address capacity building assistance (CBA) and TA needs that are essential to the success of the project.
  - Provide access to training and TA that will strengthen staff capacity relevant to all required strategies and activities of the program.

5. Provide guidance to the recipient and set standards on data collection, use, and submission requirements.
6. Provide technical advice in the development of systems to implement and advance CDC policies, initiatives and programs.
7. Collaborate to ensure coordination and implementation of technical assistance services to state and local health department HIV program staff.
8. Collaborate in assessing progress toward meeting goals/outcomes and in establishing measurement and accountability systems for documenting outcomes, such as increased performance improvements and best or promising practices
9. Provide guidance and coordinate with the recipient to improve the quality and effectiveness of the proposed program. This may include revision of the work plan, evaluation strategy, products and services, among others.
10. Foster and support ongoing opportunities for networking, communication, coordination, and collaboration.
11. Provide consultation in planning, operating, analyzing and evaluating HIV programs, including HIV prevention planning, CDC special initiatives, (e.g., program integration, comprehensive HIV prevention programs, and program evaluation activities.)
12. Monitor recipient program performance using multiple approaches, such as standardized review of performance, recipient feedback and other data reports, to support program development, implementation, evaluation, and improvement.
13. Provide support and facilitate program collaboration with other CDC programs and HHS offices to enhance and improve integration of services.
14. Assist in assessing program operations and in evaluating overall effectiveness of programs.
15. Provide capacity building assistance where identified or as needed to the recipient.
16. Collect and disseminate information, best practices, lessons learned, and evaluation results (e.g., through conferences, guidance, material development, webinars, data sharing publications, other social media, participation in meetings, committees, and working groups related to the cooperative agreement).
17. Provide requirements and expectations for standardized and other data reporting and support monitoring and evaluation activities.

**Budget Requirement:** By **September 1, 2022** the recipient must submit the following as a grant note:

**Contractual-\$1,915,367**

**The recipient must revise all contracts, to include the correct period of performance and budget and justification.**

**Expanded Authority:** The recipient is permitted the following expanded authority in the administration of the award.

- Carryover of unobligated balances from one budget period to a subsequent budget period. Unobligated funds may be used for purposes within the scope of the project as originally approved. Recipients will report use, or intended use, of unobligated funds in Section 12 "Remarks" of the annual Federal Financial Report. If the GMO determines that some or all of the unobligated funds are not necessary to complete the project, the GMO may restrict the recipient's authority to automatically carry over unobligated balances in the future, use the balance to reduce or offset CDC funding for a subsequent budget period, or use a combination of these actions.

**Program Income:** Any program income generated under this grant or cooperative agreement will be used in accordance with the Addition alternative.

Addition alternative: Under this alternative, program income is added to the funds committed to the project/program and is used to further eligible project/program objectives.

Note: The disposition of program income must have written prior approval from the GMO.

**HHS Non-Discrimination Legal Requirements for Recipients of Federal Financial Assistance:** The purpose of this Notice of Award amendment is to notify you that the Centers for Disease Control and Prevention (CDC) incorporated Department of Health and Human Services (HHS) non-discrimination legal requirements for recipients of federal financial assistance into the CDC General Terms and Conditions within your Notice of Award. The new requirements are effective immediately. The requirements are in the General Requirements section of the General Terms and Conditions, and are also listed below.

You must administer your project in compliance with federal civil rights laws that prohibit discrimination on the basis of race, color, national origin, disability, age and, in some circumstances, religion, conscience, and sex (including gender identity, sexual orientation, and pregnancy). This includes taking reasonable steps to provide meaningful access to persons with limited English proficiency and providing programs that are accessible to and usable by persons with disabilities. The HHS Office for Civil Rights provides guidance on complying with civil rights laws enforced by HHS. See <https://www.hhs.gov/civil-rights/for-providers/provider-obligations/index.html> and <https://www.hhs.gov/civil-rights/for-individuals/nondiscrimination/index.html>.

- You must take reasonable steps to ensure that your project provides meaningful access to persons with limited English proficiency. For guidance on meeting your legal obligation to take reasonable steps to ensure meaningful access to your programs or activities by limited English proficient individuals, see <https://www.hhs.gov/civil-rights/for-individuals/special-topics/limited-english-proficiency/fact-sheet-guidance/index.html> and <https://www.lep.gov/>.
- For information on your specific legal obligations for serving qualified individuals with disabilities, including providing program access, reasonable modifications, and taking appropriate steps to provide effective communication, see <http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html>.
- HHS funded health and education programs must be administered in an environment free of sexual harassment, see <https://www.hhs.gov/civil-rights/for-individuals/sex-discrimination/index.html>.
- For guidance on administering your project in compliance with applicable federal religious nondiscrimination laws and applicable federal conscience protection and associated anti-discrimination laws, see <https://www.hhs.gov/conscience/conscience-protections/index.html> and <https://www.hhs.gov/conscience/religious-freedom/index.html>.

#### **FUNDING RESTRICTIONS AND LIMITATIONS**



## Notice of Funding Opportunity (NOFO) Restrictions:

Restrictions that must be considered while planning the programs and writing the budget are:

- Recipients may not use funds for research.
- Recipients may not use funds for clinical care except as allowed by law.
- Recipients may use funds only for reasonable program purposes, including personnel, travel, supplies, and services.
- Generally, recipients may not use funds to purchase furniture or equipment. Any such proposed spending must be clearly identified in the budget.
- Reimbursement of pre-award costs generally is not allowed, unless the CDC provides written approval to the recipient.
- Other than for normal and recognized executive-legislative relationships, no funds may be used for:
  - publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body
  - the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before any legislative body
- See Additional Requirement (AR) 12 for detailed guidance on this prohibition 27 of 46 and additional guidance on lobbying for CDC recipients.
- The direct and primary recipient in a cooperative agreement program must perform a substantial role in carrying out project outcomes and not merely serve as a conduit for an award to another party or provider who is ineligible.
- In accordance with the United States Protecting Life in Global Health Assistance policy, all non-governmental organization (NGO) applicants acknowledge that foreign NGOs that receive funds provided through this award, either as a prime recipient or subrecipient, are strictly prohibited, regardless of the source of funds, from performing abortions as a method of family planning or engaging in any activity that promotes abortion as a method of family planning, or to provide financial support to any other foreign non-governmental organization that conducts such activities. See Additional Requirement (AR) 35 for applicability (<https://www.cdc.gov/grants/additionalrequirements/ar-35.html>).

Recipients may not use funds to purchase HIV Pre-exposure Prophylaxis (PrEP) medications or medications for expedited partner therapy (EPT) for STDs.

Recipients may not use funds to purchase STD medications or to support STD clinical services.

### Indirect Costs:

Indirect costs are approved based on the negotiated indirect cost rate agreement dated **March 14, 2022**, which calculates indirect costs as follows, a **Provisional** is approved at a rate of **19.0%** of the base, which includes, **direct salaries and wages including all fringe benefits**. The effective dates of this indirect cost rate are from **July 1, 2022** to **June 30, 2024**.

<b>REPORTING REQUIREMENTS</b>
-------------------------------



**Annual Federal Financial Report (FFR, SF-425):** The Annual Federal Financial Report (FFR) SF-425 is required and must be submitted to your GMS/GMO no later than **90 days** after the end of the budget period. The FFR, SF-425 is required and must be submitted through recipient online accounts in the **Payment Management System**. The FFR for this budget period is due by **October 31, 2023**. Reporting timeframe is **August 1, 2022** through **July 31, 2023**. The FFR should only include those funds authorized and disbursed during the timeframe covered by the report.

Failure to submit the required information in a timely manner may adversely affect the future funding of this project. If the information cannot be provided by the due date, the recipient is required to contact the Grants Officer listed in the contacts section of this notice before the due date.

Additional guidance on submission of Federal Financial Reports can be found at <https://www.cdc.gov/grants/documents/change-in-federal-reporting-fy-2021-recipients.pdf>.

**Annual Performance Progress Reporting:** The Annual Performance Progress and Monitoring Report (is due no later than 120 days prior to the end of the budget period, **March 30, 2023**, and serves as the continuation application for the follow-on budget period. This report should include the information specified in the solicitation from the GMS/GMO via [www.grantsolutions.gov](http://www.grantsolutions.gov).

**Performance Progress and Monitoring:** Performance information collection initiated under this grant/cooperative agreement has been approved by the Office of Management and Budget under **OMB Number 0920-1132, "Performance Progress and Monitoring Report", Expiration Date 10/31/2022**. The components of the PPMR are available for download at: <https://www.cdc.gov/grants/already-have-grant/Reporting.html> .

**Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIIS):** Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services  
Rhonda Burton, Grants Management Officer/Specialist  
Centers for Disease Control and Prevention  
Infectious Diseases Services Branch  
2939 Flowers Rd.  
Mailstop: TV-2  
Atlanta, GA 30341  
Fax: N/A  
Email: [RBurton@cdc.gov](mailto:RBurton@cdc.gov) (Include "Mandatory Grant Disclosures" in subject line)

AND

U.S. Department of Health and Human Services  
Office of the Inspector General  
ATTN: Mandatory Grant Disclosures, Intake Coordinator

330 Independence Avenue, SW  
Cohen Building, Room 5527  
Washington, DC 20201

Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line) or  
Email: [MandatoryGranteeDisclosures@oig.hhs.gov](mailto:MandatoryGranteeDisclosures@oig.hhs.gov)

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

**Prior Approval:** All requests, which require prior approval, must bear the signature of the authorized organization representative. The recipient must submit these requests by **March 30, 2023**. Additionally budget and a narrative justification of the request. budget and a narrative justification of the request.

**The following types of requests require prior approval:**

- Lift funding restriction
- Significant redirection of funds (i.e. cumulative changes of 25% of total award)
- Change in scope
- Implement a new activity or enter into a sub-award that is not specified in the approved budget
- Apply for supplemental funds
- Change in key personnel
- Extensions to period of performance

Instructions for prior approval requests can be found at:  
[CDC Prior Approvals for Non-research Awards](#)

**PROGRAM OR FUNDING GENERAL REQUIREMENTS**

**HIV Program Review Panel Requirement:** All written materials, audiovisual materials, pictorials, questionnaires, survey instruments, websites, educational curricula and other relevant program materials must be reviewed and approved by an established program review panel. A list of reviewed materials and approval dates must be submitted to the CDC Grants Management Specialist identified in the CDC Roles and Responsibilities section of this NoA.

**PAYMENT INFORMATION**

*The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to [hhstips@oig.hhs.gov](mailto:hhstips@oig.hhs.gov) or by mail to Office of the Inspector General, Department of Health and Human Services, Attn:*

*HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.*

**Payment Management System Subaccount:** Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the "P Account". Funds must be used in support of approved activities in the NOFO and the approved application.

The grant document number identified beginning on the bottom of **Page 2** of the Notice of Award must be known in order to draw down funds.

#### **CDC Staff Contacts**

**Grants Management Specialist:** The GMS is the federal staff member responsible for the day-to-day management of grants and cooperative agreements. The GMS is the primary contact of recipients for business and administrative matters pertinent to grant awards.

**The GMS contact information is located on page 1, item #9.**

**Program/Project Officer:** The PO is the federal official responsible for monitoring the programmatic, scientific, and/or technical aspects of grants and cooperative agreements, as well as contributing to the effort of the award under cooperative agreements.

**The PO contact information is located on page 1, item #10.**

**Grants Management Officer:** The GMO is the federal official responsible for the business and other non-programmatic aspects of grant awards. The GMO is the only official authorized to obligate federal funds and is responsible for signing the NoA, including revisions to the NoA that change the terms and conditions. The GMO serves as the counterpart to the business officer of the recipient organization.